http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201333032-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb596f03d029321340c965e75de6564a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate | 2012-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49ec6de748025fd72e1cb2fd472959d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cf7b5b0364e549d1ad20c3b152f5108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec06418ddb212b6c274fa2520b88edf2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9be2c9458ce01a258b04ac14e994fe8 |
| publicationDate | 2013-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201333032-A |
| titleOfInvention | Site-specific GLP-2 conjugate using immunoglobulin fragments |
| abstract | The present invention relates to a glyphosate-peptide-2 (GLP-2) conjugate comprising a raw GLP-2 or a derivative thereof covalently linked via a non-peptide polymer and an immunoglobulin Fc fragment, wherein The C-terminus of the original GLP-2 or a derivative thereof has a thiol group, and one end of the non-peptide polymer is linked to an amino acid residue of GLP-2 other than the N-terminal amine group of GLP-2; A method of preparing the GLP-2 conjugate; a pharmaceutical composition comprising the GLP-2 conjugate; and a method of using the GLP-2 conjugate to treat or prevent intestinal disease, intestinal damage or gastrosia. Since the GLP-2 conjugate of the present invention has a significantly increased GLP-2 receptor binding affinity, it is shown to prolong the half-life in vivo and enhance the durability and stability in vitro. Thus, the GLP-2 conjugates of the invention can be administered at relatively low doses and exhibit enhanced drug compliance without fluctuating blood glucose concentrations. Therefore, the long-acting GLP-2 conjugate of the present invention can be effectively used for the prevention or treatment of intestinal diseases, intestinal damage or hyperacidity. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11530249-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I794897-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I795443-B |
| priorityDate | 2011-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 247.